title: Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole.
abstract: BACKGROUND
  Sertindole is a new atypical antipsychotic drug. Preclinical pharmacology suggests that sertindole has a preferential effect on the activity of limbic and cortical dopaminergic neurons. Clinical trials have shown antipsychotic efficacy and very few extrapyramidal symptoms (EPS) with sertindole at 20 mg/day.
  
  
  OBJECTIVE
  This positron emission tomography (PET) study aimed to measure D(2) receptor occupancy in striatal and extra-striatal regions induced by clinically representative doses of sertindole in patients with schizophrenia.
  
  
  METHODS
  Four stabilized schizophrenic out-patients received sertindole 20 mg/day for 6-8 weeks. PET was performed using [(11)C]raclopride to measure D(2) receptor occupancy in the striatum and [(11)C]FLB457 to measure occupancy in the neocortex and thalamus, i.e. regions with very low D(2) receptor density.
  
  
  RESULTS
  Striatal D(2) receptor occupancy was 52-68%. Similar occupancies were found in the thalamus, and the temporal and frontal cortices.
  
  
  CONCLUSIONS
  Sertindole appears efficacious at a low D(2) receptor occupancy, comparable to that produced by clozapine. This finding could explain the low risk of EPS. The functional limbic selectivity of sertindole was not reflected in regional differences in receptor occupancy.
authors.affiliation: Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, 171 76 Stockholm, Sweden. svante.nyberg@cns.ki.se
authors.forename: Svante
authors.initials: S
authors.lastname: Nyberg
authors.forename: Hans
authors.initials: H
authors.lastname: Olsson
authors.forename: Ulrika
authors.initials: U
authors.lastname: Nilsson
authors.forename: Eli
authors.initials: E
authors.lastname: Maehlum
authors.forename: Christer
authors.initials: C
authors.lastname: Halldin
authors.forename: Lars
authors.initials: L
authors.lastname: Farde
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D003342:Corpus Striatum / Q000378:metabolism*; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D007211:Indoles / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000097:blood / Q000378:metabolism; D016037:Single-Blind Method; D013702:Temporal Lobe / Q000378:metabolism; D013788:Thalamus / Q000378:metabolism; D014055:Tomography, Emission-Computed / Q000379:methods
chemical_list: D014150:Antipsychotic Agents; D007093:Imidazoles; D007211:Indoles; D017448:Receptors, Dopamine D2; C066304:sertindole